POSC350 Health Utility Values in the STEP 1–4 Trials of Semaglutide 2.4 MG in Obesity

Abstract

Authors

H Meincke JB Bjorner T Holst-Hansen TS Grand

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×